Larimar TherapeuticsLRMR
LRMR
About: Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using novel cell-penetrating peptide technology platform. Its lead product candidate, CTI-1601, is a subcutaneously administered, recombinant fusion protein intended to deliver human frataxin (FXN) an essential protein, to the mitochondria of patients with Friedreich's ataxia.
Employees: 42
0
Funds holding %
of 6,831 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
229% more call options, than puts
Call options by funds: $2.83M | Put options by funds: $861K
225% more first-time investments, than exits
New positions opened: 26 | Existing positions closed: 8
16% more funds holding
Funds holding: 106 [Q2] → 123 (+17) [Q3]
11% more repeat investments, than reductions
Existing positions increased: 39 | Existing positions reduced: 35
0% more funds holding in top 10
Funds holding in top 10: 3 [Q2] → 3 (+0) [Q3]
1.64% less ownership
Funds ownership: 102.49% [Q2] → 100.85% (-1.64%) [Q3]
11% less capital invested
Capital invested by funds: $474M [Q2] → $421M (-$52.5M) [Q3]
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$15
349%
upside
Avg. target
$16.50
394%
upside
High target
$18
439%
upside
2 analyst ratings
2 positive
100%
0 neutral
0%
0 negative
0%
Truist Securities Joon Lee 50% 1-year accuracy 22 / 44 met price target | 439%upside $18 | Buy Initiated | 29 Jan 2025 |
HC Wainwright & Co. Edward White 33% 1-year accuracy 49 / 148 met price target | 349%upside $15 | Buy Reiterated | 24 Jan 2025 |
Financial journalist opinion
Neutral
GlobeNewsWire
3 weeks ago
Larimar Therapeutics Announces Dosing of Adolescents in Nomlabofusp Pediatric Pharmacokinetic Run-In Study for Patients with Friedreich's Ataxia
BALA CYNWYD, Pa., Jan. 23, 2025 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (Larimar) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced that dosing of adolescents 12-17 years old has started in the Company's pediatric PK run-in study for patients with Friedreich's ataxia (FA).
Positive
Seeking Alpha
1 month ago
Larimar Therapeutics: Positive Friedreich's Ataxia Data Can Only Get Better
Larimar Therapeutics, Inc. reported initial positive data from phase 2 long-term OLE study using nomlabofusp for treatment of patients with Friedreich's Ataxia; Increase of tissue FXN protein levels from 15% to 30%. The global Friedreich's Ataxia market size is projected to reach $2.06 billion by 2030. Additional data using higher 50 mg dose of nomlabofusp to treat patients with Friedreich's Ataxia expected in mid-2025.
Neutral
Benzinga
2 months ago
What's Going On With Larimar Therapeutics Stock On Tuesday?
On Monday, Larimar Therapeutics, Inc. LRMR released initial data from the ongoing long-term OLE study evaluating daily subcutaneous injections of 25 mg of nomlabofusp self-administered or administered by a caregiver in participants with Friedreich's Ataxia.
Neutral
Benzinga
2 months ago
Why Is Larimar Therapeutics Stock Trading Lower On Monday?
On Monday, Larimar Therapeutics, Inc. LRMR released initial data from the ongoing long-term OLE study evaluating daily subcutaneous injections of 25 mg of nomlabofusp self-administered or administered by a caregiver in participants with Friedreich's Ataxia.
Neutral
GlobeNewsWire
2 months ago
Larimar Therapeutics Announces Positive Initial Data from Ongoing Long-term Open Label Extension Study & Progress Across Nomlabofusp Program for Friedreich's Ataxia
BALA CYNWYD, Pa., Dec. 16, 2024 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (Larimar) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced positive initial data from the ongoing long-term OLE study evaluating daily subcutaneous injections of 25 mg of nomlabofusp self-administered or administered by a caregiver in participants with FA. The Company also provided a nomlabofusp development program update.
Positive
Zacks Investment Research
3 months ago
Zacks Industry Outlook Madrigal, Corcept, Catalyst Larimar and Theravance
Madrigal, Corcept, Catalyst Larimar and Theravance have been highlighted in this Industry Outlook article.
Positive
Zacks Investment Research
3 months ago
5 Small Drug Stocks to Buy as Trump Gets Re-Elected
Innovation is at its peak for the Zacks Medical-Drugs industry. MDGL, CORT, CPRX, LRMR and TBPH may prove to be good additions to one's portfolio.
Positive
Zacks Investment Research
3 months ago
Wall Street Analysts Think Larimar (LRMR) Could Surge 192.89%: Read This Before Placing a Bet
The mean of analysts' price targets for Larimar (LRMR) points to a 192.9% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Neutral
GlobeNewsWire
3 months ago
Larimar Therapeutics Reports Third Quarter 2024 Operating and Financial Results
BALA CYNWYD, Pa., Oct. 30, 2024 (GLOBE NEWSWIRE) -- October 30, 2024 – Larimar Therapeutics, Inc. (Larimar) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today reported its third quarter 2024 operating and financial results.
Positive
Benzinga
4 months ago
Larimar Therapeutics' New Drug Could Transform Treatment For Rare Neurological Disease, Analyst Sees Over 200% Upside For Stock
Oppenheimer has initiated coverage on Larimar Therapeutics LRMR, a clinical-stage biotechnology company focused on developing treatments for rare diseases.
Charts implemented using Lightweight Charts™